Phase I/IB Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Patients with Advanced Solid Tumors, including Pancreatic Cancer
The purpose of this phase I study is to evaluate the safety and tolerability of MGC018 in combination with lorigerlimab in patients with solid tumors, including pancreatic cancer.
Study ID: CP-MGC018-02
Trial Phase: Phase I
Trial Sponsor: MacroGenics
Therapies Used in This Trial: Lorigerlimab, MGC018